Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16

1 min

Berlin, November 5, 2022 – Bayer AG today announced that detailed results from two pivotal clinical studies have demonstrated sustained visual acuity and anatomic improvements with aflibercept 8 mg with 12- and 16-week dosing regimens versus Eylea® (aflibercept 2 mg) with 8-week dosing at week 48.The phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) respectively met their primary endpoint of non-inferiority of aflibercept 8 mg extended dosing regimens for best corrected visual acuity (BCVA) at week 48…
Read More

Like it? Share with your friends!

Send this to a friend